TrialChinese medical journal2025

Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial.

Xichun Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.